149 related articles for article (PubMed ID: 10584440)
21. Breast cancer risk reduction: what do we know and where should we go?
Prout MN
Medscape Womens Health; 2000; 5(5):E4. PubMed ID: 11113777
[TBL] [Abstract][Full Text] [Related]
22. Moving forward with breast cancer prevention.
Chen WY; Rosner B; Colditz GA
Cancer; 2007 Jun; 109(12):2387-91. PubMed ID: 17464950
[No Abstract] [Full Text] [Related]
23. Two good choices to prevent breast cancer: great taste, less filling.
Hortobagyi GN; Brown PH
Cancer Prev Res (Phila); 2010 Jun; 3(6):681-5. PubMed ID: 20522797
[TBL] [Abstract][Full Text] [Related]
24. [Chemoprevention of breast cancer. Clinical trials in pharmacological prevention].
Ricart JJ
Medicina (B Aires); 2004; 64(1):66-72. PubMed ID: 15034961
[TBL] [Abstract][Full Text] [Related]
25. Similarity of uterine mucosa changes in patients treated by raloxifen and tamoxifen.
Willèn R; Willèn H; Lindahl B
Anticancer Res; 2002; 22(2B):1121-5. PubMed ID: 12168910
[TBL] [Abstract][Full Text] [Related]
26. [Additional effect of SERM: mammary gland].
Kurebayashi J
Clin Calcium; 2004 Oct; 14(10):47-51. PubMed ID: 15577131
[TBL] [Abstract][Full Text] [Related]
27. Risk-benefit profiles of raloxifene for women.
Stefanick ML
N Engl J Med; 2006 Jul; 355(2):190-2. PubMed ID: 16837684
[No Abstract] [Full Text] [Related]
28. [Breast cancer chemoprevention. Rational, trials results and future].
Cutuli B; Lesur A; Namer M; Kerbrat P
Bull Cancer; 2009 May; 96(5):519-30. PubMed ID: 19467983
[TBL] [Abstract][Full Text] [Related]
29. Prevention of breast cancer using selective oestrogen receptor modulators (SERMs).
Powles TJ
Breast Cancer Res; 2006; 8(5):111. PubMed ID: 17049068
[TBL] [Abstract][Full Text] [Related]
30. Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease.
Jordan VC; Gapstur S; Morrow M
J Natl Cancer Inst; 2001 Oct; 93(19):1449-57. PubMed ID: 11584060
[TBL] [Abstract][Full Text] [Related]
31. Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.
Burshell AL; Song J; Dowsett SA; Mershon JL; Delmas PD; Secrest RJ; Cauley JA
Curr Med Res Opin; 2008 Mar; 24(3):807-13. PubMed ID: 18254988
[TBL] [Abstract][Full Text] [Related]
32. Women gain ground with BreastCare. Program ensures screening, treatment for poor.
Gardner N
J Ark Med Soc; 1999 Oct; 96(5):166-70. PubMed ID: 10544546
[No Abstract] [Full Text] [Related]
33. A reconsideration of tamoxifen use for breast cancer.
Wang PH; Chao HT
Taiwan J Obstet Gynecol; 2007 Jun; 46(2):93-5. PubMed ID: 17638615
[No Abstract] [Full Text] [Related]
34. [Selective estrogen receptor modulators (SERMs)].
Matsumoto T
Clin Calcium; 2006 Sep; 16(9):1520-25. PubMed ID: 16951478
[TBL] [Abstract][Full Text] [Related]
35. Hormonal interventions to prevent hormonal cancers: breast and prostate cancers.
Dunn BK; Ford LG
Eur J Cancer Prev; 2007 Jun; 16(3):232-42. PubMed ID: 17415094
[TBL] [Abstract][Full Text] [Related]
36. The science of selective estrogen receptor modulators: concept to clinical practice.
Jordan VC
Clin Cancer Res; 2006 Sep; 12(17):5010-3. PubMed ID: 16951214
[No Abstract] [Full Text] [Related]
37. [Breast cancer chemoprevention (tamoxifen, raloxifene, and others)].
Funahashi H
Nihon Rinsho; 2000 Apr; 58 Suppl():587-91. PubMed ID: 11026055
[No Abstract] [Full Text] [Related]
38. Altering the propensity for density: the benefits and risks of selective estrogen receptor modulators.
Vogel VG
Menopause; 2009; 16(6):1079-82. PubMed ID: 19779314
[No Abstract] [Full Text] [Related]
39. The lack, need, and opportunities for decision-making and informational tools to educate primary-care physicians and women about breast cancer chemoprevention.
Ravdin PM
Cancer Prev Res (Phila); 2010 Jun; 3(6):686-8. PubMed ID: 20522798
[TBL] [Abstract][Full Text] [Related]
40. A STARring role for raloxifene?
Lancet Oncol; 2006 Jun; 7(6):443. PubMed ID: 16750489
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
